People Places Practices

Recommendations

Info

Completion of Healthy Future 2015 Goals Our performance against our Healthy Future 2015 goals has helped us advance global health; steward a healthy environment; increase sustainability among our suppliers; develop engaged, health-conscious and safe employees; advance community wellness; enhance outcomes measurement in philanthropy; and increase our transparency and collaborations. Progress is reported here and in more detail within our report. Advancing Global Health Goal: One research partnership and three licensing agreements finalized to address diseases of the developing world. Actual: Our efforts to reach this goal began with commitments made in 2011 as part of the London Declaration to end Neglected Tropical Diseases (NTDs) by 2020, and include working with partners, such as Drugs for Neglected Diseases initiative (DNDi), to develop a chewable formulation of VERMOX ® (mebendazole), our treatment for intestinal worms in children. In 2013, the Company executed a data-sharing agreement with DNDi for preclinical research on flubendazole as a potential new treatment against parasites that cause lymphatic filariasis (elephantiasis) and onchocerciasis (river blindness); a licensing agreement with PATH on TMC278LA pre-exposure prophylaxis; and in-licensing agreements with Wellcome Trust and Ku Leuven in the field of dengue. We bolstered our portfolio of treatments against NTDs in 2015 when we added the early development program for dengue to our Global Public Health portfolio, aiming to develop in partnership with key research institutions innovations that protect against dengue for people traveling to and living in endemic areas. In 2014, Janssen Global Public Health expanded its collaboration with the International Partnership for Microbicides (IPM) to include worldwide development and commercialization of dapivirine for HIV prevention in women. In 2015, Janssen Sciences Ireland UC (Janssen), one of the pharmaceutical companies of Johnson & Johnson, expanded its relationship with IPM through a new agreement to help protect women against sexual transmission of HIV. This new agreement grants IPM an exclusive, royalty-free license to develop darunavir, an antiretroviral (ARV) medicine used for HIV-1 treatment, as a vaginal or rectal microbicide for HIV prevention in selected developing countries at an affordable cost. 2 A Goal: Ninety least-developed and middle-income countries have our HIV therapies registered and available at special-effort pricing. Actual: In more than 100 countries, our HIV medicines are made available either at specialeffort or reduced pricing, provided local regulatory systems allow import prior to registration. The 90 least-developed or middle-income countries identified in our Healthy Future 2015 goal are part of an HIV Access Territory from which we measure our progress. A 2. http://www.ipmglobal.org/publications/ipm-receivesworldwide-rights-hiv-prevention-medicine A Included in the scope of ERM CVS assurance engagement. Please see page 96 for their findings and conclusions. 2015 Citizenship & Sustainability Report 10
Goal: Achieve World Health Organization (WHO) prequalification for all our products that address diseases of the developing world. Actual: Since 2010, five formulations of our HIV antiretroviral medicines have achieved WHO prequalification: 75, 150 and 600 mg formulations of PREZISTA ® (darunavir) and 100 and 25 mg formulations of INTELENCE ® (etravirine). The WHO included SIRTURO ® (bedaquiline), our TB medicine, in its interim policy guidance on treatment of multidrug-resistant tuberculosis (MDR-TB) issued in June 2013. In 2014, the WHO granted prequalification for QUINVAXEM ® in cPAD, a fully liquid pentavalent vaccine (DTwP-HepB-Hib) in an innovative, compact, prefilled, auto-disable (cPAD) injection system. After embarking on an adaptive new development project to make QUINVAXEM ® available in a cPAD injection system (Becton Dickinson’s Uniject), Janssen Vaccines made the decision to stop the development of this injection system. (See the Access section of this report for more information.) Goal: Provide 200 million doses of VERMOX ® (mebendazole), our treatment for intestinal worms, to infected children in more than 30 countries. Actual: In 2015, we provided more than 129 million doses of VERMOX ® , our treatment for intestinal worms, for distribution to affected children in 14 countries. Compared with 2014, our donation decreased from 181 million doses, primarily due to challenges stemming from limited country capacity to fully utilize the amount of committed medicines. Our donations had consistently increased from 36 million doses in 2010, to 80 million in 2011, 116 million in 2012, and 161 million in 2013, to 181 million in 2014. A was registered in the U.S. and EMEA, and five generics licensing agreements were signed for our HIV medicine, rilpivirine. This registration marked achievement of the goal. A Stewarding a Healthy Environment Goal: 20 percent absolute reduction in facility carbon dioxide emissions (by 2020). Actual: Realized a 9.8 percent absolute reduction vs. 2010 baseline. A Goal: 10 percent absolute reduction in water consumption at manufacturing and R&D locations. Actual: 7.2 percent absolute reduction. Goal: 10 percent absolute reduction in total waste disposed at manufacturing and R&D locations. Actual: 2.9 percent absolute reduction. A Goal: Increase on-site renewable and cleantechnology energy capacity to 50 megawatts. Actual: 54 megawatts installed or in progress. 3 Goal: 20 percent improvement in vehicle fleet emissions efficiency. Actual: 20 percent improvement. A Goal: Products and packaging evaluated for sustainability improvements, with 60 achieving Earthwards ® recognition. Actual: 80 products have received Earthwards ® recognition. A Engaged, Health-Conscious Employees Goal: 90th percentile employee engagement when compared to external benchmarks. Actual: In 2014, engagement levels for Johnson & Johnson in total and for each of the business segments exceeded the Mayflower Global Norm. However, in 2015 a Credo survey redesign program was initiated, and engagement was not evaluated. Goal: 90 percent of employees have access to Culture of Health programs. Actual: 93 percent have access to Culture of Health programs. A Goal: 80 percent of employees have completed a health risk assessment and know their key health indicators. Actual: 92 percent have completed a health risk assessment and know their key health indicators. A Goal: 80 percent of measured employee population health risks are characterized as low risk. Actual: 73 percent of employees characterized as low risk based on employee health results. A Goal: 15 percent improvement in employee safety vs. 2010 (Lost Workday Case rate target of 0.09). Actual: Achieved 0.08 lost workday case rate, a 27 percent improvement over 2010. A Goal: 15 percent improvement in contractor safety vs. 2010 (Lost Workday Case Rate target of 0.12). Actual: Realized a lost workday case rate for contractors of 0.18, a 28.5 percent increase. A Goal: Register a new triple-combination therapy for HIV and finalize a generics licensing agreement. Actual: In 2011, a new triple-combination therapy A 3. Performance is lower than clean energy capacity reported in 2014 report (55.7 MW) based on recalculations due to divestitures. Included in the scope of ERM CVS assurance engagement. Please see page 96 for their findings and conclusions. Goal: 15 percent improvement in fleet safety vs. 2010 (Auto crashes per million miles [CPMM] target of 4.7). Actual: Realized a CPMM rate of 6.01, a nine percent increase over 2010. A 2015 Citizenship & Sustainability Report 11
Page 1 and 2: People. Places. Practices. Finding
Page 3 and 4: Our Credo We believe our first resp
Page 5 and 6: Provided below are the material are
Page 7 and 8: Sales by Geographic Region (in bill
Page 9: Citizenship & 2020 GOALS Sustainabi
Page 13 and 14: Our Materiality Assessment G4-18-21
Page 15 and 16: People We’ll help people be healt
Page 17 and 18: • Piloting and scaling therapeuti
Page 19 and 20: Tuberculosis Our goal in TB is to e
Page 21 and 22: Access & Affordability of Health Ca
Page 23 and 24: MDR-TB therapies, expanding upon th
Page 25 and 26: Innovation Innovation is critical t
Page 27 and 28: are taking an integrated approach t
Page 29 and 30: Philanthropy At Johnson & Johnson,
Page 31 and 32: implement projects that would build
Page 33 and 34: 9 Environmental Responsibility G4-1
Page 35 and 36: Product Stewardship With the world
Page 37 and 38: ® Selected Products that Received
Page 39 and 40: INCREASING RECYCLING IN THE BATHROO
Page 41 and 42: Our Ingredients & Raw Materials Our
Page 43 and 44: Progressive palm oil policies and p
Page 45 and 46: Climate Human health and environmen
Page 47 and 48: Energy Use 18 We made good progress
Page 49 and 50: Energy Consumption in Terajoules Fa
Page 51 and 52: goods transport, we work with our t
Page 53 and 54: Percentage of Water Consumption Ant
Page 55 and 56: that will enable focused environmen
Page 57 and 58: Notable Waste Reduction Projects, 2
Page 59 and 60: Governance & Ethical Performance Ou
Page 61 and 62:
Supply Chain The Customer is at the
Page 63 and 64:
triggers to allow escalation of sig
Page 65 and 66:
Supply Chain Risk Management Johnso
Page 67 and 68:
Procurement & Supplier Management T
Page 69 and 70:
EN33, LA15, HR11, S010 Responsible
Page 71 and 72:
• Support initiatives to verify s
Page 73 and 74:
42 Human Rights G4-58 Johnson & Joh
Page 75 and 76:
Labor Practices 44, 45 & Workforce
Page 77 and 78:
We currently have 11 Board members,
Page 79 and 80:
Employee Recruitment, Development &
Page 81 and 82:
Workplace 50 Health & Safety functi
Page 83 and 84:
lower in Asia-Pacific, EMEA and Lat
Page 85 and 86:
Health-Conscious, 54 Safe Employees
Page 87 and 88:
These services are centered on prev
Page 89 and 90:
Employee Diversity & Inclusion Our
Page 91 and 92:
Stakeholder Engagement G4-24-G4-27
Page 93 and 94:
and individuals; and recognizing ex
Page 95 and 96:
Report Profile G4-13, G4-23, G4 28-
Page 97 and 98:
2015 Data Summary Table Employee He
Page 99 and 100:
2015 Data Summary Table Environment
Page 101 and 102:
2015 Data Summary Table 21 Operatio
Page 103 and 104:
United Nations Global Compact Envir
Page 105 and 106:
Global Reporting Initiative (GRI) I
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
show all

People Places Practices

Create successful ePaper yourself

Delete template?

Save as template?